

RESEARCH ARTICLE

Open Access



# Novel prokaryotic expression of thioredoxin-fused insulinoma associated protein tyrosine phosphatase 2 (IA-2), its characterization and immunodiagnostic application

Luciano Lucas Guerra, Natalia Inés Faccinetti, Aldana Trabucchi, Bruno David Rovitto, Adriana Victoria Sabljic, Edgardo Poskus, Ruben Francisco Iacono and Silvina Noemí Valdez\*

## Abstract

**Background:** The insulinoma associated protein tyrosine phosphatase 2 (IA-2) is one of the immunodominant autoantigens involved in the autoimmune attack to the beta-cell in Type 1 Diabetes Mellitus. In this work we have developed a complete and original process for the production and recovery of the properly folded intracellular domain of IA-2 fused to thioredoxin (TrxIA-2<sub>ic</sub>) in *Escherichia coli* G1698 and G1724 strains. We have also carried out the biochemical and immunochemical characterization of TrxIA-2<sub>ic</sub> and design variants of non-radiometric immunoassays for the efficient detection of IA-2 autoantibodies (IA-2A).

**Results:** The main findings can be summarized in the following statements: i) TrxIA-2<sub>ic</sub> expression after 3 h of induction on G1724 strain yielded  $\approx 10$  mg of highly pure TrxIA-2<sub>ic</sub>/L of culture medium by a single step purification by affinity chromatography, ii) the molecular weight of TrxIA-2<sub>ic</sub> (55,358 Da) could be estimated by SDS-PAGE, size exclusion chromatography and mass spectrometry, iii) TrxIA-2<sub>ic</sub> was properly identified by western blot and mass spectrometric analysis of proteolytic digestions (63.25 % total coverage), iv) excellent immunochemical behavior of properly folded full TrxIA-2<sub>ic</sub> was legitimized by inhibition or displacement of [<sup>35</sup>S]IA-2 binding from IA-2A present in Argentinian Type 1 Diabetic patients, v) great stability over time was found under proper storage conditions and vi) low cost and environmentally harmless ELISA methods for IA-2A assessment were developed, with colorimetric or chemiluminescent detection.

**Conclusions:** *E. coli* G1724 strain emerged as a handy source of recombinant IA-2<sub>ic</sub>, achieving high levels of expression as a thioredoxin fusion protein, adequately validated and applicable to the development of innovative and cost-effective immunoassays for IA-2A detection in most laboratories.

**Keywords:** IA-2, Recombinant protein expression, Diabetes Mellitus, Autoantibody, Autoimmunity, Immunoassay, *Escherichia coli*

\* Correspondence: silval@ffyb.uba.ar; valdesilvina@gmail.com  
Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Estudios de la Inmunidad Humoral "Prof. Ricardo A. Margni" (IDEHU), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina

## Background

The insulinoma associated protein tyrosine phosphatase 2 (IA-2) is a 106 kDa (979 residues) transmembrane glycoprotein [1–3] whose encoding gene is localized in human chromosome 2q35. IA-2 is expressed in neuroendocrine cells, such as the peptidergic neurons of the central nervous system, the chromaffin cells present in the adrenal medulla and the endocrine pancreas (alpha and beta-cells of the pancreatic islet) [3–5]. IA-2 belongs to the protein tyrosine phosphatase (PTP) family, particularly to the receptor type PTPs; however, it lacks such enzymatic activity [6, 7]. In pancreatic islets, IA-2 participates in the cytoplasmic transport of dense core secretory granules (DSG) containing insulin, its subsequent excretion into the extracellular space, biogenesis, storage and recycling, as well as in beta-cell proliferation [8–12]. The IA-2 structure consists of three domains: the extracellular domain (residues 1–576, which are in contact with the DSG lumen during storage) that is separated from the intracellular domain or IA-2<sub>ic</sub> (residues 601–979, oriented to the beta-cell cytoplasm) by a single transmembrane domain (residues 577–600). It was demonstrated that, after exocytosis, calpain mediates the release of IA-2<sub>ic</sub> from the plasma membrane; a process after which IA-2 travels to the nucleus where its inactive PTP domain binds to the phosphorylated tyrosine present in the STAT5 protein, thus upregulating gene expression of DSG proteins, including insulin and IA-2 [13–16].

Diabetes Mellitus (DM) is a group of metabolic diseases of heterogeneous etiology characterized by poor metabolic control of patients and the presence of marked hyperglycemia, which stems from defects in insulin secretion and/or action [17]. According to the American Diabetes Association, DM can be classified into four main groups: Type 1, Type 2, gestational and other types. Type 1 DM (T1DM) is characterized by the destruction of pancreatic beta-cells leading to a deficiency in insulin secretion that results in elevated blood glucose levels [18–20]. The loss of tolerance to pancreatic islet antigens is known to be mediated by a T cell-dependent autoimmune process. IA-2 is one of the immunodominant autoantigens involved in the autoimmune attack on the beta-cell in DM. The other autoantigens implicated are: insulin, glutamic acid decarboxylase (GAD) and Zinc transporter 8 (ZnT8). The autoantibodies specific to insulin, GAD, IA-2 and ZnT8 (IAA, GADA, IA-2A and ZnT8A, respectively) can be detected in patient sera as the first detectable sign of emerging beta-cell autoimmunity [21–23]. These autoantibodies are currently used as additional serological markers to confirm the autoimmune process underlying insulin deficiency in diabetic patients. These markers are useful for predicting T1DM in children and to achieve

the correct diagnosis in adult patients with intermediate forms of DM, like Latent Autoimmune Diabetes of the Adults (LADA) [24–26].

IA-2A mostly recognize the IA-2<sub>ic</sub> (essentially the PTP sequence, residues 696–979), since this domain is the one exposed upon cell damage. IA-2A bind to discontinuous epitopes, therefore, the correct folding of IA-2<sub>ic</sub> is critical for immune recognition [27–30]. Moreover, the diagnostic sensitivity in both newly diagnosed type 1 diabetic patients and pre-diabetic individuals is highest when IA-2<sub>ic</sub> is used as antigen for IA-2A recognition, thus suggesting that this domain should be used as detection antigen in T1DM-related autoantibody screening studies [31, 32]. Approximately, 60–80 % of patients with T1DM are positive for IA-2A [33, 34]. The probability of T1DM patients' first-degree relatives contracting DM within 5 years from the detection of the positive marker is 65–85 % for IA-2A (positive predictive value), since these autoantibodies are known to appear later during the development of the autoimmune process. Therefore, the detection of IA-2A can be considered indicative of rapid disease progression [35, 36].

The assessment of a complete set of autoantibodies is not only applied to confirm the existence of an underlying autoimmune process in infant-juvenile or adult diabetic patients (clinical classification of DM), and to monitor first-degree relatives of diabetic individuals (population at risk), but also to predict the need for insulin treatment. Besides, the presence of autoantibodies can be used as inclusion criteria for enrolment in prediction and prevention trials and as an endpoint in observational studies [31, 37–40]. The usefulness of IA-2A detection lies in its high diagnostic specificity, since the frequency of such a marker in healthy individuals is only 2–4 % [31, 41, 42]. The reference method for detection of IA-2A is the Radioligand Binding Assay (RBA) [43], which includes a recombinant radiolabelled autoantigen as tracer for immunocomplex formation in a fluid phase. This tracer is usually synthesized in cell-free eukaryotic systems, bearing [<sup>35</sup>S]-marked aminoacids, making it environmentally inappropriate, expensive and limited to authorized laboratories. The development of more accurate, sensitive and inexpensive methods to detect IA-2A can be helpful to achieve an early diagnosis or prediction of DM. For these reasons, a handy source of properly folded recombinant antigen is needed for the development of innovative and cost-effective non-radiometric immunoassays for the quasi-quantitative assessment of IA-2A (such as solid phase ELISA-type assays) that are applicable to low or medium complexity laboratories [44].

The most widespread recombinant expression system is the prokaryotic one employing *Escherichia coli*. This system has proved to be easy to handle, it is inexpensive

and the protein expression yield is high [45, 46]. Different fusion partners are often used to facilitate solubilisation and/or purification of eukaryotic proteins in this system, such as the glutathione-S-transferase, the manose binding protein or thioredoxin (Trx) [47–49]. We have previously described the expression of IA-2 in *E. coli*; however, the recombinant protein obtained was not stable enough to be implemented in the routine diagnosis of autoimmune DM [50]. In this work we have developed a complete and original process for the production and recovery of the properly folded intracellular domain of IA-2 fused to Trx (TrxIA-2<sub>ic</sub>) in a prokaryotic expression system with high performance. We have also carried out the biochemical and immunochemical characterization of TrxIA-2<sub>ic</sub> and design variants of non-radiometric immunoassays for the efficient detection of IA-2A using the stable recombinant antigen produced.

## Methods

### Sera collection

#### *Argentinian healthy control individuals*

Control sera ( $n = 115$ , mean age of 29.7 years with median age of 25, range 16 to 80 and male/female: 58/57) were obtained from Argentinian healthy individuals without personal or family history of DM or autoimmune diseases. The sample collection was approved by the Ethics Committee of the José de San Martín Clinical Hospital, University of Buenos Aires (UBA), Buenos Aires, Argentina. All subjects were informed about the purpose of the study, and a signed consent for study participation was obtained. Autoantibodies assessment was performed and all of the individuals were negative. Sera were stored at  $-20\text{ }^{\circ}\text{C}$  until assayed.

#### *Argentinian Type 1 diabetic patients*

Serum samples ( $n = 60$ , mean age of 9.2 years with median age of 9, range 2 to 21 and male/female: 23/37) were collected from Argentinian children and adolescents admitted to the Nutrition Service at Gutiérrez National Pediatric Hospital, Buenos Aires, Argentina, from May 2013 to March 2015. Samples from patients fasted overnight (ON) were taken before or within 72 h of starting insulin treatment. T1DM was diagnosed according to WHO criteria [51]. Sample collection and protocols were approved by the Ethics Committees of the Gutiérrez National Pediatric Hospital. Parental consent was obtained. Sera were stored at  $-20\text{ }^{\circ}\text{C}$  until assayed.

#### *Rabbit polyclonal sera against IA-2*

Recombinant IA-2<sub>ic</sub> fused to a C-terminal His-tag (IA-2<sub>ic</sub>His<sub>6</sub>) was obtained as previously described by Sica et al [50]. IA-2 antibodies were obtained through immunization of New Zealand white rabbits ( $n = 3$ )

with 0.1 mg of IA-2<sub>ic</sub>His<sub>6</sub> emulsified in complete Freund's adjuvant. The initial injection was followed by booster injections with 0.1 mg of IA-2<sub>ic</sub>His<sub>6</sub> in incomplete Freund's adjuvant at three-week intervals. Rabbits were bled 15 days after the booster dose.


#### *Rabbit polyclonal sera against thioredoxin*

Recombinant Trx was expressed in *E. coli* with the pTrx vector (Invitrogen, Carlsbad, CA, USA) and purified by osmotic shock according to the manufacturer's instructions. The product was dialyzed against phosphate-buffered saline (PBS, 1.5 mM KH<sub>2</sub>PO<sub>4</sub>, 8.1 mM Na<sub>2</sub>HPO<sub>4</sub>, 0.14 M NaCl, 2.7 mM KCl, and pH 7.4) and lyophilized. The antiserum against Trx was obtained by immunizing New Zealand white rabbits ( $n = 3$ ) with 1.0 mg of recombinant Trx emulsified in complete Freund's adjuvant. The initial injection was followed by booster injections with 1.0 mg of Trx in incomplete Freund's adjuvant at four-week intervals. Rabbits were bled 15 days after boosting. All animals were housed under specific conditions according to the "Guide for the Care and Use of Laboratory Animals" by the National Research Council of the National Academies (USA); experiments were performed in compliance with the Argentinian animal protection laws and approved by the "Prof. Ricardo A. Margni" Humoral Immunity Studies Institute (IDEHU), National Research Council (CONICET-UBA).

#### *IA-2<sub>ic</sub> expression as a fusion protein with thioredoxin in E. coli*

##### *Expression vector and E. coli transformation*

Unless otherwise indicated, standard molecular-biology protocols were used [52]. The coding sequence of human IA-2<sub>ic</sub> (residues 604 to 979) was adapted from the sequences found in NCBI GenBank (L18983.1: Homo sapiens tyrosine phosphatase (IA-2/PTP) mRNA, complete cds). Human IA-2<sub>ic</sub> codons were customized to those used with the highest frequencies in *E. coli* (codon optimization). The IA-2<sub>ic</sub> optimized nucleotide sequence was synthesized by GenScript (GenScript Corporation, Piscataway, NJ, USA; www.GenScript.com), including *Sma*I and *Xba*I restriction sites at the 3' and 5' ends, respectively. The synthesized construct (1128 bp) was obtained from GenScript in plasmid pUC57 and maintained in JM109 *E. coli* (Promega, Madison, WI, USA). After vector propagation and purification with QIAprep spin Miniprep Kit (QIAGEN, Hilden, Germany), the IA-2<sub>ic</sub> construct was released with *Sma*I and *Xba*I and ligated to the pTrxFus linearized vector (Invitrogen, Carlsbad, CA, USA) to yield pTrxIA-2<sub>ic</sub> (Fig. 1). The quality of the new vector encoding the fusion protein TrxIA-2<sub>ic</sub> was corroborated by sequencing (Macrogen Inc, Seoul, Korea). Competent *E. coli* GI698 (Invitrogen,



Carlsbad, CA, USA) and GI724 (ATCC<sup>®</sup> 55151™) strains were transformed with pTrxIA-2<sub>ic</sub> by electroporation.

#### Protein expression and *E. coli* disruption

Bacteria were cultured at 30 °C in 0.2 % w/v casein amino acids, 0.5 % w/v glucose, 1 mM MgCl<sub>2</sub>, and 100 µg/mL ampicillin, and protein expression was induced with 100 µg/mL tryptophan at 20 °C for GI698 or 37 °C for GI724. Different timepoints during the course of the induction period were collected; including 1.5, 3.0 and 16.0 h. Before and after the induction of protein expression, bacterial pellets from 1 mL culture were collected by centrifugation, suspended in 0.2 mL of SDS-PAGE sample buffer (50 mM Tris-HCl, 12 % w/v glycerol, 0.005 % w/v bromophenol blue, 4 % w/v SDS, 4 % v/v 2-mercaptoethanol -2ME-, pH 6.8) and boiled for 5 min to obtain the total cell lysate (TCL). A bacterial pellet was collected from 200 mL culture by centrifugation, suspended in 2 mL lysis buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.0) and sonicated in the presence of 1 mM 2ME and protease inhibitors (0.1 % w/v aprotinin and 2 mM phenylmethylsulfonyl fluoride) over crushed ice. After sonication, Triton X-100 was added to a

final concentration of 0.1 % v/v and incubated for 10 min at 0 °C. The intracellular soluble fraction (ISF) was then separated by centrifugation at 15,000 rpm for 10 min at 4 °C.

#### Purification by affinity chromatography

TrxIA-2<sub>ic</sub> was purified by means of affinity chromatography following the protocol previously described [53]. The resin was based on an agarose support covalently modified with phenylarsine oxide (Additional file 1: Figure S1), which permitted the binding of proteins containing vicinal dithiol residues, as in Trx [54]. This resin, previously equilibrated in lysis buffer (≈4 mL) and activated with four column volumes (CV) of lysis buffer containing 20 mM 2ME, was added to the lysate (4 mL), and the resulting suspension was incubated for 1.5 h at 4 °C. The resin was poured into a column (0.7 cm × 9.0 cm) and washed sequentially with six CV lysis buffer, six CV lysis buffer containing 1 mM 2ME and three CV lysis buffer containing 5 mM 2ME. Bound proteins were eluted with several 2 mL of the lysis buffer containing 100 mM 2ME. The protein concentration in purified fractions was determined using the Coomassie Plus (Bradford) Assay kit (ThermoScientific, Rockford, IL, USA). Aprotinin was added to a final concentration of 0.1 % w/v.

#### Biotinylation of TrxIA-2<sub>ic</sub>

Two mL of the purified fusion protein were subjected to buffer exchange to PBS using a ZEBRA desalt spin column (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's instructions. The desalted protein was then incubated for 2 h at 0 °C with a 20-fold molar excess of sulfo-NHS-biotin (Pierce Biotechnology, Rockford, IL, USA). Free biotin was removed on a new ZEBRA desalt spin column. Higher biotinylation rates were also tested with a 435-fold excess of sulfo-NHS-biotin.

#### Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and western blot analysis

TCL and ISF were analyzed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions, followed by Coomassie Brilliant Blue R-250 staining [55], and western blot (WB) [56]. For comparison, all SDS-PAGE lanes in each gel contained proteins recovered from the same amount of cells. Protein bands were transferred to nitrocellulose membranes and unoccupied binding sites were blocked by incubating with 3 % w/v skim milk in Tris buffer saline (TBS; 0.05 M Tris-HCl, 0.15 M NaCl, pH 7.5) for 2 h at room temperature (RT). After 3 washing steps with 0.05 % v/v Tween 20 in TBS (TBS-T) membranes were incubated ON at RT with polyclonal sera to Trx or

IA-2 diluted 1/100 in 3 % w/v skim milk, 0.05 % v/v Tween 20 in TBS (TBS-MT), and then washed five times with TBS-T. Bound antibodies were visualized by incubation with peroxidase-conjugated goat antibodies to rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) diluted 1/2000 in TBS-MT, followed by the addition of alpha-chloronaphthol (Sigma-Aldrich, Inc., St Louis, MO) and 10 vol H<sub>2</sub>O<sub>2</sub>.

### Biochemical characterization of TrxIA-2<sub>ic</sub>

#### *Molecular weight determination by SDS-PAGE*

The general SDS-PAGE procedure consisted in separating several conventional protein standards with known molecular weight (MW) (Amersham Pharmacia Biotech, Little Chalfont Buckinghamshire, England) in parallel with a TrxIA-2<sub>ic</sub> sample in a 10 % T, 6 % C acrylamide gel with 1.5 mm thickness and under reducing conditions [55]. The standard proteins were used to generate a curve correlating MW and migration in the gel (relative mobility or R<sub>f</sub>), from which the MW of the TrxIA-2<sub>ic</sub> sample was estimated.

#### *Analytical size-exclusion chromatography*

Size-Exclusion chromatography (SEC) was performed on an FPLC ÄKTA system (GE Healthcare, Sweden) equipped with a Superdex 75 HR 10/30 column (Pharmacia Biotech, Uppsala, Sweden). The chromatographic process was performed at RT with PBS as mobile phase at a flow rate of 1.0 mL/min and the absorbance was monitored at 280 nm. The MW, hydrodynamic dimension and aggregation state were assessed [57]. SEC calibration curves were generated, employing MW standard proteins (gel filtration standard, Bio-Rad, Hercules, CA, USA), using linear regression analysis of the plot of peak elution volume (V<sub>e</sub>) vs. the logarithm of their MW, obtained from chromatographic trace. In parallel, purified TrxIA-2<sub>ic</sub> (50 µg/500 µL) was injected and the V<sub>e</sub> obtained was interpolated in the calibration plot in order to estimate MW and aggregation state of the sample.

#### *Mass spectrometry analysis*

In order to assess total protein MW, affinity purified TrxIA-2<sub>ic</sub> was subjected to mass spectrometry (MS) analysis. Briefly, a 1 µL aliquot of the sample was spotted onto an AnchorChip (Bruker, Billerica, MA, USA). One µL of an oversaturated solution of sinapinic acid in 30/70/0.1 % v/v acetonitrile/water/TFA was added to the sample and left to crystallize by air-drying. Samples were analyzed on a Bruker Microflex MALDI-TOF device (Bruker, Billerica, MA, USA). In order to further characterize and identify the protein, TrxIA-2<sub>ic</sub> was subjected to proteolytic digestion and MS analysis. Concisely, the sample was dissolved in 50 mM NH<sub>4</sub>HCO<sub>3</sub>

buffer, pH 8; a volume equivalent to 20 µg was subjected to disulfide bond reduction, with 20 mM dithiothreitol for 45 min at 56 °C, and alkylation with 20 mM iodoacetamide for 45 min at RT in the dark. The sample was then diluted to a final concentration of 1 M urea. Finally, trypsin and chymotrypsin proteolytic digestion were performed separately and samples were analyzed by nanoHPLC (EASY-Spray Accucore, Thermo scientific, West Palm Beach, FL, USA) coupled to a mass spectrometer with Orbitrap technology (Q-Exactive, Thermo Scientific, West Palm Beach, FL, USA; at Centro de Estudios Químicos y Biológicos por Espectrometría de Masa -CEQUIBIEM- CONICET-UBA, Argentina), enabling both separation and identification of peptides. Ionization of samples was made by electrospray (EASY-SPRAY, Thermo Scientific, West Palm Beach, FL, USA) and data analysis was performed by the Proteome Discoverer software version 1.4, Thermo Scientific. Coverage percentages were calculated based on the number of identified peptides/total number of peptides.

### Immunochemical characterization of TrxIA-2<sub>ic</sub>

#### *Synthesis of [<sup>35</sup>S]IA-2 tracer*

The [<sup>35</sup>S]IA-2 tracer was obtained by in vitro transcription/translation of the cDNA coding for human IA-2<sub>ic</sub> cloned into pSP64 vector (Promega, Madison, WI, USA), using a rabbit reticulocyte lysate system (Promega, Madison, WI, USA) in the presence of [<sup>35</sup>S]-methionine (New England, Nuclear, Boston, MA, USA), according to the manufacturer's instructions. Translation products were diluted in radioimmunoassay (RIA) buffer (0.02 M Tris-HCl, 0.15 M NaCl, 0.1 % v/v Tween 20, pH 7.4) and applied to a PD10 column (Pharmacia-LKB Biotechnology, Uppsala, Sweden) in order to remove free [<sup>35</sup>S]-methionine. Typically, the percentage of incorporation of [<sup>35</sup>S]-methionine to the protein by this method was 5–7 %, yielding about 5–7 × 10<sup>6</sup> cpm of labelled protein. The tracer was stored in aliquots at -40 °C, and had a shelf life of 5 weeks.

#### *Radioimmunoassay protocol*

Quantitative competition assays were performed by standard Radioimmunoassay (RIA) protocols. The incubation of 2.5 µL of IA-2A(+) Type 1 diabetic patient sera with 10,000 cpm of [<sup>35</sup>S]IA-2 in the presence of serial concentrations (90.0 pM – 0.6 µM in a final volume of 60 µL) of purified TrxIA-2<sub>ic</sub> from ISF was performed in duplicate. After ON incubation, 50 µL of 40 % v/v protein A-Sepharose 4B FF (GE Healthcare Biosciences, Uppsala, Sweden) in RIA buffer were added and incubated for 2 h at RT on an end-over-end shaker. Subsequently, samples were allowed to settle and the supernatants were discarded in order to isolate immunocomplexes. Pellets were washed three times with 200 µL

of RIA buffer and once with 200  $\mu\text{L}$  of 0.2 M NaCl in RIA buffer. Finally, pellets were suspended in 100  $\mu\text{L}$  of 1 % w/v SDS and supernatants were carefully transferred to vials for scintillation counting (1 min/tube). Results for each sample were calculated as Bound% (B%) =  $100 \times (\text{bound cpm}/\text{total cpm})$ . Inhibitory Dose-response curves [log (inhibitor) vs. response - Variable slope (four parameters)] were fitted to the mathematical function:

$$B/B_0 = B/B_{0\min} + (B/B_{0\max} - B/B_{0\min}) / (1 + 10^{[(\log IC_{50} - \log TrxIA-2_{ic} \text{ dose}) * \text{Hill Slope}]})$$

Where B corresponds to B% measurements,  $B_0$  is the B% at zero concentration of unlabelled antigen,  $B/B_{0\min}$  and  $B/B_{0\max}$  are the minimal and maximal response, respectively and the parameter  $IC_{50}$  represents the concentration of TrxIA-2<sub>ic</sub> that gave a response half between  $B/B_{0\min}$  and  $B/B_{0\max}$ . Hill Slope describes the steepness of the family of curves. The same protocol was performed for TrxIA-2<sub>ic</sub>-biotin, in serial concentrations of 12.0 pM – 0.7  $\mu\text{M}$ .

#### **Inhibition assay**

The ability of TrxIA-2<sub>ic</sub> to compete with [<sup>35</sup>S]IA-2 for the binding to antibodies was assessed qualitatively by incubating sera from 30 IA-2A(+) Type 1 diabetic patients with the tracer in the presence of TrxIA-2<sub>ic</sub> excess (190 nM). Briefly, 2.5  $\mu\text{L}$  of human sera were incubated ON at 4 °C with 10,000 cpm of [<sup>35</sup>S]IA-2 in the absence or presence of unlabelled TrxIA-2<sub>ic</sub> in a final volume of 60  $\mu\text{L}$  in RIA buffer. Immunocomplexes were isolated with protein A-Sepharose 4B FF; pellets were washed and suspended in 1 % w/v SDS, as described in the RIA protocol. The radioactivity of supernatants was counted. Results for each sample (with or without TrxIA-2<sub>ic</sub>) were calculated as B%, and expressed as Standard Deviation scores (SDs) =  $(B\% - B_c\%) / SD_c$ , where  $B_c\%$  is the mean B% of healthy control sera and  $SD_c$  its standard deviation. The same protocol was followed for TrxIA-2<sub>ic</sub>-biotin in the presence of antigen excess (140 nM).

#### **Storage and stability studies**

Inhibition dose-response curves were performed over time as previously described. Briefly, a 2.5  $\mu\text{L}$  aliquot of a pool of sera from 5 IA-2A (+) Type 1 diabetic patients was incubated with the tracer [<sup>35</sup>S]IA-2 and several dilutions of purified TrxIA-2<sub>ic</sub> in two different storage conditions. These conditions included TrxIA-2<sub>ic</sub> stored at -20 °C with or without the addition of glycerol to a final concentration of 50 % v/v in lysis buffer either with 100 mM 2ME or 50 mM 2ME, respectively. The study was performed over the course of 120 days and dose-response curves of log [TrxIA-2<sub>ic</sub>] vs.  $B/B_0$  were analyzed at each time for both conditions. The parameter

$IC_{50}$  was selected for comparison and selection of the optimal storage condition.

#### **TrxIA-2<sub>ic</sub> application in immunoassays for IA-2A assessment**

##### **Reagents**

PBS was used as the microplate coating buffer. Two percent w/v skim milk in PBS (PBS-M) and PBS containing 0.05 % v/v Tween 20 (PBS-T) were used as blocking solution and washing buffer, respectively. Sample or reagent dilutions were prepared in 2 % w/v skim milk, 0.05 % v/v Tween 20 in PBS (PBS-MT). Immuno-pure Avidin was purchased from Pierce, and Avidin-Horseradish Peroxidase (HRP) and rabbit anti-human IgG-HRP were purchased from Jackson ImmunoResearch Laboratories, Inc. The 3,3',5,5'-tetramethyl-benzidine/ $\text{H}_2\text{O}_2$  (Single Component TMB Peroxidase EIA Substrate Kit, BioRad, Hercules, CA, USA) was employed as the chromogenic substrate and the SuperSignal ELISA Pico (ThermoScientific, Rockford, IL, USA) as the chemiluminescent substrate. Except when otherwise indicated, incubations were performed at RT, washing steps were performed with PBS-T and 50  $\mu\text{L}$  per well were added in each incubation step.

##### **Radioligand binding assay (RBA) protocol**

RBA was performed as previously described [43] with minor modifications [50, 58]. Briefly, 2.5  $\mu\text{L}$  of human sera were incubated ON at 4 °C with 10,000 cpm of [<sup>35</sup>S]IA-2 in a final volume of 60  $\mu\text{L}$  in RIA buffer. After that, 50  $\mu\text{L}$  of 40 % v/v protein A-Sepharose 4B FF in RIA buffer were added and incubated for 2 h at RT on an end-over-end shaker. Subsequently, samples were allowed to settle and the supernatants were discarded in order to isolate immunocomplexes. Pellets were washed three times with 200  $\mu\text{L}$  of RIA buffer and once with 200  $\mu\text{L}$  of 0.2 M NaCl in RIA buffer. Finally, pellets were suspended in 100  $\mu\text{L}$  of 1 % w/v SDS and supernatants were carefully transferred to vials for scintillation counting (1 min/tube). Results for each sample were calculated as Bound% (B%) =  $100 \times (\text{bound cpm}/\text{total cpm})$ , and expressed as Standard Deviation scores (SDs) =  $(B\% - B_c\%) / SD_c$ , where  $B_c\%$  is the mean B% of healthy control sera and  $SD_c$  its standard deviation. Samples were considered positive when SDs > 3. This assay had 66.0 % sensitivity, 97.8 % specificity and 86.43 % accuracy in the Islet Autoantibody Standardization Program (IASP) 2015, laboratory 0519.

##### **Blank corrected ELISA with colorimetric detection (*b<sub>c</sub>*-ELISA)**

The protocol employed was based on those previously described [50, 59–61], with minor modifications. Briefly, polystyrene microplates (Maxisorp, NUNC, Roskilde, Denmark) were coated ON at 4 °C with 0.50  $\mu\text{g}$  purified

avidin per well, in coating buffer and washed five times with PBS. Blocking solution (200  $\mu$ L/well) was added, and plates were incubated for 1.5 h. Microplates were washed three times, and incubated for 4 h at 4 °C with 20.0 ng of TrxIA-2<sub>ic</sub>-biotin. After washing six times, duplicate serum samples diluted 1/10 were added and incubated ON at 4 °C. To measure the non-specific signal, duplicates of serum samples were incubated in wells without TrxIA-2<sub>ic</sub>-biotin. Plates were washed six times, and bound antibodies were detected with anti-human IgG-HRP (diluted 1/20,000, 1.5 h at 4 °C). After washing (five times plus one final wash with PBS), the chromogenic substrate was added and plates were incubated in the dark. The color reaction was stopped with 2 M H<sub>2</sub>SO<sub>4</sub>. The oxidized substrate was measured at 450 nm with an ELISA plate reader Multiskan EX (Thermo electron corporation, Vantaa, Finland). Results were calculated as specific absorbance ( $A_s$ , mean of each sample minus the mean of their non-specific control), and expressed as SDs =  $(A_s - A_c) / SD_c$ , where  $A_c$  is the mean specific absorbance of healthy control sera and  $SD_c$  its standard deviation. The cut-off value of the assay was set at SDs = 1.6.

#### Bridge ELISA with chemiluminescent detection (CL-<sub>b</sub>ELISA)

The protocol employed was based on those previously described [62–65]. White Polystyrene microplates (96 F Maxisorp white microwell, ThermoScientific, Rockford, IL, USA) were coated ON at 4 °C with 40.0 ng of purified TrxIA-2<sub>ic</sub> per well, washed three times with PBS, blocked for 1.5 h with 200  $\mu$ L of blocking solution, and washed five times. Samples were added in duplicate and microplates were incubated for 1 h. Plates were then washed five times and 2.0 ng of TrxIA-2<sub>ic</sub>-biotin per well were added (the TrxIA-2<sub>ic</sub>-biotin employed was synthesized with high rates of biotinylation). After another 1 h incubation, plates were washed five times and bound TrxIA-2<sub>ic</sub>-biotin was detected by the addition of Avidin-HRP diluted 1/500. After 1 h incubation, microplates were washed four times plus one final washing step with 200  $\mu$ L of PBS; the chemiluminescent substrate was added and incubated 1 min in the dark. The chemiluminescent reaction was measured in a Victor<sup>3</sup> multilabel reader (Perkin Elmer, MA, USA). Results were calculated as specific counts per second (cps<sub>s</sub>, mean of each sample minus the mean of blank wells), and expressed as SDs =  $(cps_s - cps_c) / SD_c$ , where  $cps_c$  is the mean specific cps of healthy control sera and  $SD_c$  its standard deviation. Samples were considered positive when SDs > 2.5.

#### Statistical analysis

The identity and parallelism between inhibitory dose-response curves obtained with TrxIA-2<sub>ic</sub> and TrxIA-

2<sub>ic</sub>-biotin were analyzed by comparing  $B/B_{0min}$ ,  $B/B_{0max}$ , Hill slopes and  $IC_{50}$  values by the extra sum-of-squares F test comparison method. Normal distribution of data was analyzed by the D'Agostino and Pearson omnibus normality test. In order to remove outliers from normally distributed healthy control individuals, the Rout test was performed. The selection of optimal cut-off values was based on curves constructed by plotting the calculated specificity and sensitivity of each protocol vs. the corresponding cut-off values. Statistical significance was evaluated using parametric tests: paired samples Student *t* test and unpaired samples Student *t* test with Welch correction, or non-parametric tests: Wilcoxon matched-pairs signed rank test or Mann-Whitney *U*-test for unpaired data, when applicable. The correlation between methods for IA-2A assessment was calculated using the non-parametric Spearman Rank Correlation. Calculations were performed using GraphPad Prism version 6.01 for Windows (GraphPad Software, San Diego California, USA, www.graphpad.com). A *p*-value < 0.05 was considered statistically significant.


## Results

### IA-2<sub>ic</sub> expression as a fusion protein with thioredoxin in *E. coli*

Competent *E. coli* GI698 and GI724 strains were transformed with pTrxIA-2<sub>ic</sub> by electroporation. Protein expression was induced with Trp in both strains at different incubation times and temperatures (20 °C and 37 °C for GI698 and GI724, respectively) in order to achieve optimal conditions for maximal protein production. For this analysis, SDS-PAGE and WB for TCL were carried out with specific protein recognition by polyclonal serum to Trx. Figure 2a and b depicts bands compatible with TrxIA-2<sub>ic</sub> theoretical MW ( $\approx$ 55.4 kDa) in both bacteria strains, whereas such bands are absent in TCL from non-transformed bacteria under the same experimental conditions. Maximal protein expression was detected at 16 h post-induction in TCL from both strains. In order to select the optimal temperature and time for induction, bacteria were harvested and lysed as previously described. The ISF was isolated from both strains at each induction time, and analyzed by SDS-PAGE and WB (Fig. 2c and d). Relative protein expression was compared at 3.0 h after induction, where GI724 strain showed slightly higher values than GI698 as regards the  $\approx$  55.4 kDa band from the total protein mass. Furthermore, almost total loss of protein from ISF in GI724 strain was observed at 16.0 h after induction.

### Purification of TrxIA-2<sub>ic</sub>

TrxIA-2<sub>ic</sub> was purified from the ISF of *E. coli* GI724 lysate after 3 h of induction. The procedure was based on affinity chromatography in which the Trx portion of



**Fig. 2** IA-2<sub>ic</sub> expression as a fusion protein with Trx in *E. coli* Gl698 and Gl724. **a** and **c**: SDS-PAGE (12.1 % T 6.0 % C, 1 mm, under reducing conditions, stained with Coomassie Brilliant Blue R-250), **b** and **d**: WB revealed with a rabbit polyclonal serum to thioredoxin as primary antibody. Samples: Total Cell Lysate for **a** and **b**, Intracellular Soluble Fraction for **c** and **d**. Lanes 1-4: samples from pTrxA-2<sub>ic</sub> transformed *E. coli* Gl698 strain; lanes 5-8: samples from pTrxA-2<sub>ic</sub> transformed *E. coli* Gl724 strain. Lanes 1 and 5: sample before induction (0 h); lanes 2 and 6: sample after 1.5 h of induction; lanes 3 and 7: sample after 3.0 h of induction; lanes 4 and 8: sample after 16.0 h of induction. Arrows indicate the electrophoretic mobility of TrxA-2<sub>ic</sub>

TrxA-2<sub>ic</sub> binds to the resin by its catalytic domain containing vicinal dithiols. Figure 3 depicts SDS-PAGE and WB of different stages of purification, with high levels of protein expression revealed (lane 1). One-step purification separated most contaminant proteins with little or no significant loss of TrxA-2<sub>ic</sub> relying on the high capacity of the in-house made resin. Based on the quantification of the 100 mM 2ME fraction (lanes 6–9) bands, the purification yielded  $\approx 10$  mg of 72–77 % pure TrxA-2<sub>ic</sub>/L of culture medium.


#### Biochemical characterization of TrxA-2<sub>ic</sub>

In order to estimate the MW of TrxA-2<sub>ic</sub>, an SDS-PAGE with MW calibrators (phosphorilase b, bovine albumin, ovalbumin, carbonic anhydrase, trypsin inhibitor and alpha lactalbumin) was performed. A calibration curve of log MW vs.  $R_f$  was constructed ( $\log \text{MW} = -0.9091 \times R_f + 4.9932$ ,  $R^2 = 0.9932$ ) and the unknown MW of TrxA-2<sub>ic</sub> was interpolated. An experimental MW (55,943 Da) compatible to the theoretical MW (55,358 Da) was obtained (1.1 % error, which is a satisfactory accuracy for this method) [66]. Moreover, further MW studies were carried with SEC in order to characterize TrxA-2<sub>ic</sub> hydrodynamic behavior and the presence of aggregates (Fig. 4a). These

results revealed the presence of monomeric and dimeric forms of TrxA-2<sub>ic</sub> with the corresponding estimated MW (61,187 Da and 98,047 Da, respectively). Values were obtained from a calibration curve of log MW vs.  $V_e$  ( $\log \text{MW} = -0.1969 \times V_e + 6.7149$ ,  $R^2 = 0.9906$ ). For TrxA-2<sub>ic</sub> identification in eluted fractions, a WB using rabbit polyclonal serum to IA-2 was performed, confirming the presence of the fusion protein at expected monomeric and dimeric MW. In fact, by subjecting the dimer to reduction with dithiothreitol, total conversion into the monomer state was observed (Additional file 2: Figure S2). Moreover, SEC showed a TrxA-2<sub>ic</sub> Stokes radius of 33.2 Å for the monomer peak, which corresponded to a globular protein of 64,816 Da.

MS analysis of TrxA-2<sub>ic</sub> corroborated the agreement between the chimera MW and the expected value (actual mass 55,209.008 Da; theoretical mass 55,357.500 Da) (Additional file 3: Figure S3). The purified fusion protein was also subjected to proteolytic digestion with trypsin and chymotrypsin. The peptide profile obtained after digestion was analyzed by Orbitrap mass spectrometry, achieving 63.25 % total coverage (38.15 % for trypsin and 42.77 % for chymotrypsin) of TrxA-2<sub>ic</sub> (498 residues) (Fig. 4b and c), considering high confidence peptides only; when low confidence peptides were not filtered, 95.38 %





coverage of the theoretical composition of the protein was accounted for.

#### Immunochemical characterization of TrxIA-2<sub>ic</sub>

Dose-response curves with 4 IA-2A RBA positive Type 1 diabetic patient sera were performed by RIA, adding TrxIA-2<sub>ic</sub> at variable concentrations and using [<sup>35</sup>S]IA-2 synthesized in an eukaryotic system (Fig. 5a). All dose-response curves (log [TrxIA-2<sub>ic</sub>] vs. B/B<sub>0</sub>) showed similar IC<sub>50</sub> (ranging from 4.57×10<sup>-9</sup> to 1.30×10<sup>-8</sup> M), indicating comparable TrxIA-2<sub>ic</sub> immunoreactivity with sera. The immunochemical ability of TrxIA-2<sub>ic</sub> to compete with [<sup>35</sup>S]IA-2 was assessed qualitatively by incubating 30 Type 1 diabetic patients sera in the presence of 190 nM TrxIA-2<sub>ic</sub> (Fig. 5b). All tested sera were IA-2A positive with SDs of 17.00 ± 8.29 (mean ± SD), median 14.90, range 4.24 to 35.09 and cut-off value for positivity SDs = 3.0. A significant difference between sera from Type 1 diabetic patients and healthy control individuals was observed (Unpaired samples Student *t* test with Welch correction, *p* < 0.0001). All type 1 diabetic patient sera became virtually negative under antigen excess (comparable to healthy control individuals SDs); median SDs changed from 14.90 to -0.16

(range -1.31 to 4.73) with cold TrxIA-2<sub>ic</sub> excess (Wilcoxon test for paired samples, *p* < 0.0001).


Competitive quantitative and qualitative assays were also performed for TrxIA-2<sub>ic</sub>-biotin in order to evaluate any distortion in epitopes caused by biotinylation. The immunochemical identities between TrxIA-2<sub>ic</sub> and TrxIA-2<sub>ic</sub>-biotin were analyzed and expressed in terms of parallelism. As seen in Fig. 5c, when using a pool of IA-2A+ human sera, parallelism and identity between curves was achieved (one curve adequately fits all data, alpha = 0.05, R<sup>2</sup> = 0.9492). Similar results were obtained for TrxIA-2<sub>ic</sub> biotinylated under conditions of high biotin concentrations (Additional file 4: Figure S4). The inhibition assay for TrxIA-2<sub>ic</sub>-biotin was performed by incubating 30 Type 1 diabetic patient sera in the presence of 140 nM TrxIA-2<sub>ic</sub>-biotin (Fig. 5d). All tested sera were IA-2A positive with an SDs of 14.16 ± 4.17 (mean ± SD), median 13.53, range 7.68 to 22.27 and a cut-off value for positivity SDs = 3.0. It can be observed that sera from Type 1 diabetic patients differed significantly from healthy control samples (Unpaired *t* test with Welch correction, *p* < 0.0001). All patient sera became virtually negative (comparable to healthy control individuals) under antigen excess: mean SDs changed from 14.16 to 0.01 (median -0.67, range -2.52 to 4.13) with cold TrxIA-2<sub>ic</sub>-biotin excess (Student *t* test for paired samples, *p* < 0.0001).

#### Storage and stability studies

Displacement curves were performed over time (120 d) using a pool of 5 sera from IA-2A positive Type 1 diabetic patients and the tracer [<sup>35</sup>S]IA-2 in competition with cold TrxIA-2<sub>ic</sub> under different storage conditions. Inhibition dose response curves (log [TrxIA-2<sub>ic</sub>] vs. B/B<sub>0</sub>) were drawn for each condition and the IC<sub>50</sub> value was determined and plotted against time (Fig. 5e). As it can be observed, the IC<sub>50</sub> values remained relatively constant over time for the storage condition of -20 °C in 50 % v/v glycerol, 50 mM 2ME lysis buffer, indicating that the immunoreactivity was maintained throughout the evaluation period. Contrarily, the storage condition at -20 °C in 100 mM 2ME lysis buffer caused a gradual increase in the IC<sub>50</sub> value until *t* = 120 d, when the dose-response curve could no longer be properly fitted.

#### TrxIA-2<sub>ic</sub> application in immunoassays for IA-2A assessment

Forty eight sera from children and adolescents with T1DM were tested in parallel by RBA, <sub>bc</sub>ELISA and CL-<sub>b</sub>ELISA for IA-2A detection. The specificity was calculated as 100 % minus the percentage of false positives, using control individuals (*n* = 37, 23 or 39 for RBA, <sub>bc</sub>ELISA and CL-<sub>b</sub>ELISA, respectively). In order to establish normally distributed results for healthy



**Fig. 4** Biochemical characterization of TrxA-2<sub>ic</sub>. **a**: Size Exclusion Chromatography of affinity-purified TrxA-2<sub>ic</sub> (solid line) and molecular weight globular calibrators (dotted line) performed on a Superdex 75 column (insert: calibration curve). The detector was set at 280 nm. From left to right, calibrator peaks correspond to human gamma-globulin (158 kDa), ovalbumin (44 kDa), horse myoglobin (17 kDa) and B<sub>12</sub> vitamin (1.35 kDa). Arrows indicated peaks from monomeric ( $V_e = 9.793$  mL) and dimeric TrxA-2<sub>ic</sub> ( $V_e = 8.753$  mL). **b**: TrxA-2<sub>ic</sub> sequence. Underlined and highlighted in bold are those fragments identified by Orbitrap Mass Spectrometry considering high confidence peptides. **c**: TrxA-2<sub>ic</sub> N-terminal Trx fraction, the linker peptide and the IA-2<sub>ic</sub> fragment in the C-terminal of the construction are detailed in the scheme above, and the corresponding peptide fragments identified by Orbitrap Mass Spectrometry are highlighted in the diagram below. JM: Juxtamembrane

control individuals, outlier removal was needed (Rout test,  $Q = 1$  %); however, these outliers were included in all plots and also for specificity calculations, as they were considered false positives. When analyzed by RBA, 42 sera were positive (87.5 %), while 6 were negative (12.5 %). A median SDs of 13.74 was obtained, ranging from -0.84 to 57.08; cut-off value for positivity SDs = 3.0 (Fig. 6a and Table 1). With this analysis, a specificity of 97.3 % was obtained and healthy control individuals differed significantly from T1DM patients ( $p < 0.0001$ ).


Results were obtained from healthy control and newly diagnosed T1DM patient sera ( $n = 48$ ).

By <sub>bc</sub>ELISA, a total of 19 sera out of the 48 T1DM patients analyzed were positive (39.6 % sensitivity), with SDs ranging from -2.76 to 4.85, and an SDs =  $1.01 \pm 1.55$  (mean  $\pm$  SD), median 1.05 and cut-off value for positivity SDs = 1.6. Out of the 42 IA-2A positive sera by RBA, 17 scored positive by <sub>bc</sub>ELISA, whereas 29 patients were negative (Fig. 6b). These results indicated that <sub>bc</sub>ELISA had an analytical sensitivity of 40.5 % for this sera collection (percentage of patients RBA positive that were positive by <sub>bc</sub>ELISA) and 95.7 % specificity when analysis of healthy control sera was performed (Table 1). It is noteworthy that the RBA failed to render positive reactions


in 2 patients that were indeed detected by the <sub>bc</sub>ELISA. Populations significantly differed for median antibody levels ( $p = 0.0032$ ).

Out of the 48 patient sera, 28 scored positive for IA-2A by CL-<sub>b</sub>ELISA (58.3 % sensitivity), whereas 20 patients were negative (41.7 %) (Fig. 6c). Twenty five IA-2A positive sera by RBA scored positive when evaluated by CL-<sub>b</sub>ELISA, showing an analytical sensitivity of 59.5 %, SDs ranging from -0.71 to 111.20 and a median SDs = 3.46 (Table 1). Healthy control sera ( $n = 39$ ) resulted in 94.9 % specificity and showed two different statistical populations that needed outliers removal by the Rout test ( $Q = 1$  %). Remaining results were normally distributed. In order to achieve maximum analytical sensitivity for this protocol, SDs > 2.5 was chosen as the cut-off value. As seen for <sub>bc</sub>ELISA, CL-<sub>b</sub>ELISA detected 3 positive sera that the RBA could not, one of which was positive for <sub>bc</sub>ELISA as well. Populations significantly differed for median antibody levels ( $p < 0.0001$ ).

The Venn's diagram (Fig. 6d) depicts the integrated results of RBA, <sub>bc</sub>ELISA, and CL-<sub>b</sub>ELISA. As shown on this figure, 12 out of 48 sera were positive by RBA, <sub>bc</sub>ELISA, and CL-<sub>b</sub>ELISA, while 2 were negative by all methods. Five sera were only positive by both



**Fig. 5** Immunochemical characterization and storage study. **a**: Dose-response curves for 4 IA-2A RBA positive Type 1 diabetic patient sera incubated with different concentrations of TrxIA-2<sub>ic</sub>. Each curve includes best-fit values from the log (inhibitor) vs. response - Variable slope (four parameters) equation: correlation coefficient data ( $R^2$ ),  $IC_{50}$  values and an approximation to the affinity constant of IA-2A ( $K_A$ ) calculated as the inverse of  $IC_{50}$ . **b**: Inhibition capacity of TrxIA-2<sub>ic</sub> assessed in 30 IA-2A positive type 1 diabetic patient sera in the absence (left) or presence (right) of TrxIA-2<sub>ic</sub>. Twenty healthy control sera were used in order to set a cut-off value. **c**: Dose-response curves for a pool of 3 IA-2A RBA positive Type 1 diabetic patient sera for different concentrations of TrxIA-2<sub>ic</sub> (open circle, solid line) and TrxIA-2<sub>ic</sub>-biotin (closed circle, dotted line). **d**: Inhibition capacity of TrxIA-2<sub>ic</sub>-biotin assessed in 30 IA-2A positive Type 1 diabetic patient sera in the absence (left) or presence (right) of TrxIA-2<sub>ic</sub>-biotin. Twenty healthy control sera were used in order to set a cut-off value. Binding is expressed as SDs, and the dotted lines represent the cut-off value. **e**:  $IC_{50}$  vs. storage time for TrxIA-2<sub>ic</sub> stored at  $-20\text{ }^\circ\text{C}$  in 100 mM 2ME lysis buffer (solid line) and  $-20\text{ }^\circ\text{C}$  in 50 % glycerol, 50 mM 2ME lysis buffer (dotted line). These assays were performed by standard RIA protocols, as described in Methods.



**Table 1** Analytical parameters from RBA,  $bc$ ELISA and  $CL$ - $b$ ELISA

| Assay                                   | RBA           | $bc$ ELISA   | $CL$ - $b$ ELISA |
|---|---------------|--------------|------------------|
| Healthy control individuals (n)         | 37            | 23           | 39               |
| Type 1 diabetic patients (n)            |               | 48           |                  |
| Median (SDs)                            | 13.74         | 1.05         | 3.46             |
| Range (SDs)                             | (-0.84)-57.08 | (-2.76)-4.85 | (-0.71)-111.20   |
| Sensitivity <sup>a</sup> (%)            | 87.5          | 39.6         | 58.3             |
| Specificity <sup>b</sup>                | 97.9          | 95.7         | 94.9             |
| Analytical Sensitivity <sup>c</sup> (%) | -             | 40.5         | 59.5             |

<sup>a</sup>Percentage of IA-2A positive patients from the total population studied

<sup>b</sup>100 % minus the percentage of false positives

<sup>c</sup>Percentage of patients RBA positive that were positive by each method

RBA and  $bc$ ELISA, while 13 were only positive by both RBA and  $CL$ - $b$ ELISA. Moreover,  $bc$ ELISA and  $CL$ - $b$ ELISA were able to detect 4 patients that were found negative by RBA (1 serum found positive only by  $bc$ ELISA, 2 sera positive only by  $CL$ - $b$ ELISA and 1 sera positive by both methods). The latter sera were not considered false positives since these samples had been obtained from newly diagnosed patients with T1DM.  $CL$ - $b$ ELISA was able to detect 15 IA-2A positive sera that  $bc$ ELISA was not; whereas  $bc$ ELISA detected 6 patients as IA-2A positive that  $CL$ - $b$ ELISA did not. The Spearman correlation coefficient ( $r = 0.6650$  for  $bc$ ELISA and  $CL$ - $b$ ELISA) and p value ( $p = 0.0005$ ) showed that the pairing was significantly effective and there was an acceptable concordance between antibody levels by RBA and either solid phase tests was found.

## Discussion

Although radiometric methods have an excellent performance in the diagnosis of DM, the use of radioactive isotopes is falling out of use because of their multiple disadvantages (high costs, waste management difficulties, low applicability in laboratories, centralization of determinations, etc.). Therefore, the development of alternative methods of acceptable performance, greater simplicity, lower cost and more applicability in low complexity laboratories are needed. The methods most widely used include solid phase immunoassays which require large amounts of antigen for their development and routine application. Our laboratory has previously attempted to produce recombinant IA-2<sub>ic</sub> in order to implement ELISA-like tests [50]; however, due to the instability of the product (Poskus E, personal communication) the RBA for IA-2A remains the method of choice for routine analysis in Argentina.

In this work, an alternative approach for IA-2<sub>ic</sub> expression was developed. The methodology presented herein involved the production of soluble cytoplasmic IA-2<sub>ic</sub> by means of the solubilising effect of Trx [49], which is a phenomenon already observed for other proteins [67–70]. The use of the Trx fusion partner increases the chance of correct folding, which is critical for binding of autoantibodies from patients with T1DM. The expression of TrxIA-2<sub>ic</sub> was accomplished in *E. coli* GI698 and GI724 strains (Fig. 2). High production levels of the C-terminal fusions to thioredoxin were obtained through the use of pTrxFus vector carrying pL, which is a strong bacteriophage  $\lambda$  promoter. As advised, collection of samples at different timepoints during the course of the induction period was carried out in order to evaluate variations in protein solubility, stability and concentration [49, 71]. The lysis of harvested bacteria was performed and the ISF evaluation was carried out (Fig. 2). Even though a substantial expression of TrxIA-2<sub>ic</sub> was observed in both strains, GI724 showed a slightly higher protein expression under shorter induction periods than GI698. The expression of soluble TrxIA-2<sub>ic</sub> became minimal under ON incubations in the GI724 strain, which was expected for large induction times under higher temperatures. It can be speculated that under such conditions, TrxIA-2<sub>ic</sub> became unstable due to the excessive synthesis and improper folding, a phenomenon that led to insolubilisation and product accumulation in the form of inclusion bodies (IB). This observation was corroborated by SDS-PAGE and WB of isolated IB (Additional file 5: Figure S5). On the other hand, the expression in GI698 strain rendered good levels of protein, with a maximum at 16 h of induction, and minimal visualization of degradation by-products, probably due to low activity of proteases at 20 °C. Although GI698 strain should not be completely ruled out as a valuable source of TrxIA-2<sub>ic</sub>,

shorter induction times are preferred for scaling up procedures. Taking into account these results, the expression in GI724 strain employing a 3 h induction time, was selected as optimal condition for TrxIA-2<sub>ic</sub> production in any low-medium complexity laboratory and was therefore used for further studies.

The purification of TrxIA-2<sub>ic</sub> from the ISF was accomplished by a single step of affinity chromatography using an agarose-based matrix with arsenic residues. This chemical ligand binds selectively to vicinal dithiols, such as the ones present in the catalytic site of Trx (binding motif Cys-Gly-Pro-Cys). The levels of soluble protein expression obtained in *E. coli* GI724 were higher than those previously reported in the literature for prokaryotic systems [72, 73]. High purity levels were achieved, even higher than those reported in the results section (72–77 %), which does not include the contribution of TrxIA-2<sub>ic</sub> dimer. Furthermore, these unique properties of the fusion partner allowed us to establish a general platform for expression and purification of soluble Trx fusion proteins, such as TrxGAD and TrxPI [68, 70], along with TrxIA-2<sub>ic</sub>, applicable to the laboratory diagnosis of autoimmune DM. The amount of protein obtained with this methodology was suitable for the development of solid phase IA-2A immunoassays; in fact, the result of a standard purification protocol may allow passive adsorption of more than 500 96-well polystyrene microplates. Taking into account these results, the affinity purified TrxIA-2<sub>ic</sub> from ISF was further characterized.

The first quality control step was to verify if TrxIA-2<sub>ic</sub> had the theoretical expected MW. The analysis of the purified protein by SDS-PAGE, SEC and MS rendered results that coincided, within the experimental error, with the theoretical MW values calculated from the sequence. Furthermore, we observed that under native conditions, both a monomeric form and aggregates of a dimer-like conformation would coexist when solubilised. The SDS-PAGE analysis employing dithiothreitol demonstrated that these dimers were bound by covalent bonds, specifically disulfide bonds (Additional file 2: Figure S2). According to literature [74], the cysteine residues were unlikely to form disulfide bonds, contributing little to the three dimensional structure of the protein. Probably, disulfide bridges are formed later due to the action of reactive oxygen species during storage or the IA-2<sub>ic</sub> PTP and juxtamembrane domains tendency to dimerize [75–77], leading to polymerization. This in vitro observation could be a resemblance of the in vivo regulation of many receptor-type PTPs. Furthermore, the oxidation of the core cysteine (C909) to cysteic acid would block access of antibodies, which turns storage buffer a critical aspect in the stability of IA-2<sub>ic</sub> [78]. For this reason, we decided to maintain the 2ME reducing

conditions after purification. Regarding the determination of the Stokes radius of the protein, since TrxIA-2<sub>ic</sub> is a 55,358 Da protein, the hydrodynamic behavior was compatible with a properly folded monomer that deviates moderately from an ideal sphere (different elution behaviour between the standard and the unknown proteins) [66]. Upon performing MS analysis after proteolytic digestion, sequence coverage of 63.25 % was achieved over the 498 residues constituting the TrxIA-2<sub>ic</sub>, which is a percentage suitable to accomplish the autoantigen identification. Taking into account the biochemical characterization of the entire protein, we have expressed genuine human IA-2<sub>ic</sub> as a fusion protein with Trx.

Immunochemical studies of TrxIA-2<sub>ic</sub> allowed us to demonstrate that the protein is able to displace the binding of radiolabeled eukaryotic IA-2<sub>ic</sub> from IA-2A, thus confirming the integrity of conformational epitopes in the recombinant antigen, which is a critical requirement to IA-2A recognition. It is noteworthy that the approximate  $K_a$  values obtained for 4 sera were in the order of  $10^8$  M<sup>-1</sup>, which correlates with literature data ( $10^7$ – $10^{11}$  M<sup>-1</sup>) [79]. Since the calculated  $K_a$  for IA-2A were, within the limits of experimental error, the same for TrxIA-2<sub>ic</sub> and these previously published data for IA-2<sub>ic</sub> from *E. coli*, it can be speculated that the epitopes as well as the overall protein conformation are not affected during prokaryotic expression and Trx fusion. Furthermore, with a larger number of IA-2A positive patient sera, we demonstrated that they were able to recognize recombinant TrxIA-2<sub>ic</sub>, displacing the radioactively labelled eukaryotic antigen. Considering that most sera from type 1 diabetic patients only target conformational discontinuous epitopes of IA-2<sub>ic</sub> [29], this result reinforces the hypothesis of a correct folding of epitopes in the IA-2<sub>ic</sub> portion, probably due to the presence of energetically or kinetically favourable conditions.

Even though an EK site was included in the plasmid, a further enzymatic removal of the Trx portion from the fusion protein to avoid cross reaction phenomena was not necessary since we have previously demonstrated that healthy control and diabetic sera do not react with bacterial Trx [53]. Therefore, we have decided to use the entire fusion protein for the development of immunoassays since Trx did not interfere with IA-2A recognition, it helped in proper protein folding and stability, and even simplified purification. Furthermore, the amino group of the N-terminal portion of Trx could be useful to improve the orientation of IA-2<sub>ic</sub> on surfaces with free carboxyl residues by covalent bonds, such as those required in Surface Plasmon Resonance CM5 sensor chips for thermodynamic and kinetic studies of autoantibodies, and in polystyrene microspheres for flow cytometry [53, 80].

In order to increase the possibilities for immunoassay development, TrxIA-2<sub>ic</sub> was biotinylated. When the immunochemical behavior of TrxIA-2<sub>ic</sub>-biotin was studied, the dose-response curves generated by RIA showed identity between TrxIA-2<sub>ic</sub> and its biotinylated counterpart, according to the general principles of immunochemical cross reactivity [81]. Furthermore, competitive qualitative assays showed that all patient sera became virtually negative under TrxIA-2<sub>ic</sub>-biotin excess. All these results indicate that the recognition by IA-2A of both TrxIA-2<sub>ic</sub> and the biotinylated protein was practically the same; therefore, it could be deduced that the biotinylation did not alter critical epitopes for interaction with IA-2A.

Stability studies in the storage condition at -20 °C in 100 mM 2ME lysis buffer indicated that as TrxIA-2<sub>ic</sub> storage time proceeds, the displacing concentration required for a response half between  $B/B_{0min}$  and  $B/B_{0max}$  ( $IC_{50}$ ) was increasing to the point of no longer being recognized by IA-2A. However, TrxIA-2<sub>ic</sub> immunoreactivity was maintained throughout the evaluation period when the fusion protein was kept at -20 °C in 50 % v/v glycerol, 50 mM 2ME lysis buffer. For this reason, the latter storage condition was selected, which ensured immunochemical quality of the recombinant antigen for at least four months, being applicable to routine immunoassays for the detection of IA-2A. This finding is one of the most interesting properties of the protein under study, as previous attempts in our laboratory failed to obtain IA-2<sub>ic</sub> with sufficient stability to yield immunoassays for routine applications, as most of the soluble protein precipitated within 24 h.

Since TrxIA-2<sub>ic</sub> could be expressed in a simple prokaryotic system with high yields, purity and stability, and it was properly identified and immunoreactive against IA-2A positive patient sera, we proceeded to apply this protein in non-radiometric methods for IA-2A detection. To start with, a population of 48 children and adolescents with newly diagnosed T1DM were subjected to IA-2A assessment by the reference method RBA, which shows the best sensitivity and specificity parameters in international quality controls (such as the Diabetes Autoantibody Standardization Program –DASP– and IASP). As previously described [64, 82], it is currently accepted that RBA alone is not enough to rule out the existence of autoimmunity in childhood diabetic patients; therefore, the performance of simultaneous determinations of all major markers (IAA, GADA, IA-2A and ZnT8A) is recommended. In this work, we managed to develop two methods capable of detecting IA-2A in some sera that RBA could not, probably due to differences in the principles of detection [83–85]. It has also been demonstrated that fluid phase radiometric assays may underestimate the IA-2A titers due to the formation

of insoluble immune complexes which do not bind to Protein A-Sepharose, a phenomenon that would not occur in solid phase immunoassays [86].

The first alternative method,  ${}_{bc}$ ELISA, included the development of a solid phase immunoassay, based on a standard design for detection of antibodies, similar to an indirect ELISA, characterized by the immobilization of the biotinylated antigen to the microplate via an avidin bridge [50, 61]. This design emerged as a viable option for solving the possible denaturation of the protein when adsorbed onto the plastic surface of the microplate [87], which would be deleterious for IA-2A binding mainly because they recognize discontinuous epitopes. Unfortunately, the performance parameters showed a narrow dynamic range and high signals with healthy control sera, with the consequent low sensitivity (39.6 %) and relative sensitivity (40.5 %) unsuitable for routine application. Another drawback of this assay is the requirement of a large sample volume, which makes it impractical when children and juvenile patients must be assessed. However, these performance values do not differ much from previous data corresponding to the same design for IA-2A [50, 59, 60] or GADA [61]. The poor performance could not be attributed to alterations in critical epitopes for recognition by IA-2A since it was shown that TrxIA-2 ${}_{ic}$ -biotin exhibited immunoreactivity comparable to TrxIA-2 ${}_{ic}$ . This phenomenon could be attributed to differences in the principles of antigen:antibody interaction (fluid phase vs. solid phase) and detection (radiometric vs. colorimetric).

In order to improve the performance in IA-2A assessment, we proceeded to the optimization of  ${}_{CL-b}$ ELISA, the first described test for the determination of IA-2A with chemiluminescent detection. While this detection shows increased sensitivity, it can lead to higher non-specific signal as well. For this reason we decided to develop an immunoassay variant with high specificity. One way to reduce the background signal is to use the labelled specific antigen to detect bound antibody instead of the detection of total bound IgG with labelled xenogeneic anti-immunoglobulin antibody, which decreases the signal-to-background ratio [65]. Previous data obtained by our research group have shown that this design has acceptable performance values for the clinical application in routinely GADA determination in conventional ELISA or flow cytometry-based immunoassays [64, 82]. The design is based on the immobilization of the antigen to the solid phase, the incubation with the specific autoantibody (crosslinking molecule) and a fluid phase interaction with the biotinylated antigen via the available paratope. For detection of IA-2A, we demonstrated that it presented a wide dynamic range, even higher than that described for the reference method. The parameters of sensitivity (58.3 %), relative sensitivity (59.5 %) and specificity (94.9 %), although lower than

those for RBA, are more than acceptable for use as a first line screening method for assessing humoral markers. It is difficult to compare the performance of this assay with those of previous studies where IA-2A is detected because in those studies different antigens were used, as well as different patient populations and healthy control individuals (with variables such as number, ethnicity and, possibly, sample matrix) [62, 63, 74–77]. The lower sensitivity showed by  ${}_{CL-b}$ ELISA, in comparison with RBA, could be a consequence of partial denaturation of TrxIA-2 ${}_{ic}$  when adsorbed onto the surface of polystyrene microplates. Concerning the epitopes recognized by IA-2A, it was previously found that these autoantibodies mostly recognize the C-terminal domain of IA-2 [33]. Thus, it is not surprising that the Trx moiety, which is an N-terminal extension of Trx-IA-2 ${}_{ic}$ , did not adversely affect the sensitivity of the ELISAs reported here. The lack of correlation between solid-phase and liquid-phase assays has been previously reported and discussed [84, 88–90]. In this sense, different thermodynamic principles apply to ELISA and RBA, since in the latter antigen–antibody reaction occurs in the liquid phase, in high dilution and near the equilibrium; meanwhile in both ELISA protocols the interaction occurs in solid phase, where the amount of immunocomplexes is highly dependent on antibodies concentration. In fact, in T1DM, autoantibodies concentration is really low (in the order of  $10^{-12}$  M), turning their detection into an analytical challenge using solid phase assays, especially for sensitivity limitations. Then, as expected, there was a low correlation between the results obtained by both ELISA protocols and RBA. This protocol also used a lower volume of sera than  ${}_{bc}$ ELISA, but still higher than that used in RBA (2.5  $\mu$ L of undiluted sera). Concerning healthy control individuals, the presence of possible false positive may be due to a matrix effect caused by samples from patients who did not have the proper fasting as diabetic patients did. As mentioned above, the presence of anti-Trx crossreactivity in healthy control sera could be ruled out [53]. When a comparison was made with  ${}_{bc}$ ELISA,  ${}_{CL-b}$ ELISA had higher values for the above mentioned analytical parameters. In addition, the differences in dynamic range between methods can be explained, at least partially, by higher sensitivity with chemiluminescent detection and increased signal-to-background ratio in immunoassay design. As regards differential detection of immunoglobulin isotypes, while  ${}_{CL-b}$ ELISA can potentially detect any, other immunoassays have limitations for binding specificity to the antibody conjugated to peroxidase ( ${}_{bc}$ ELISA) or protein A (RBA). In order to better characterize the performance of  ${}_{CL-b}$ ELISA, we increased the number of type 1 diabetic patients ( $n = 60$ ) and healthy controls ( $n = 115$ ) samples already tested (Additional file 6: Figure S6). As a result, a

sensitivity of 56.7 %, an analytical sensitivity of 59.6 % and a specificity of 97.4 % were obtained. It is noteworthy that in the DASP and the IASP the number of samples that are received to evaluate the analytical performance of different immunoassays is similar to the number used in this work. Employing a higher number of samples, the sensitivity values remained fairly the same; however a slightly increased in the specificity of the assay was observed since the percentage of detected outliers decreased in a more representative population. This data reinforces the applicability of CL<sub>b</sub>ELISA in IA-2A routine determination.

## Conclusion

The findings of this study can be summarized in the following statements: i) the recombinant vector pTrxIA-2<sub>ic</sub> was designed, synthesized and quality-controlled, ii) soluble human IA-2<sub>ic</sub> was expressed as a properly folded thioredoxin fusion protein in *E. coli*, iii) higher levels of TrxIA-2<sub>ic</sub> expression were obtained after 3 h of induction on GI724 strain, iv) highly pure TrxIA-2<sub>ic</sub> was recovered from the intracellular soluble fraction after a single step purification by affinity chromatography, v) the MW of TrxIA-2<sub>ic</sub> could be estimated by SDS-PAGE, SEC and MS, vi) the presence of TrxIA-2<sub>ic</sub> soluble monomers and covalent-mediated dimers was determined under native conditions, vii) TrxIA-2<sub>ic</sub> was properly identified by WB and MS, viii) excellent immunochemical behavior of properly folded full TrxIA-2<sub>ic</sub> was validated by inhibition or displacement of [<sup>35</sup>S]IA-2 binding from IA-2A, ix) great stability over time was found under proper storage conditions and x) low cost and environmentally harmless non-radiometric methods for IA-2A assessment were developed, which are accessible to many laboratories.

Furthermore, methods for IA-2A detection by flow cytometry based on the use of polystyrene microspheres, with the potential simultaneous determination of the main humoral markers of autoimmune DM are currently being developed in our laboratory [64], since multiplex testing will facilitate high-throughput screening of T1DM in the general population [91]. It is clear that better tests based on pure antigen preparations will allow better screening of DM risk, characterizing the course of the disease and the distinction between DM of immune origin and that of metabolic cause.

## Additional files

**Additional file 1: Figure S1.** Affinity purification of thioredoxin fusion proteins with an agarose-based support covalently modified with phenylarsine oxide. Thioredoxin fusion proteins, containing vicinal dithiols in their active site (CysGlyProCys region), reversibly bind the hydrophobic trivalent arsenic functional site and are eluted using 2-mercaptoethanol (2ME). Affi-Gel 10 (Bio-Rad Laboratories Inc.) was used as the agarose-based support. (PDF 170 kb)

**Additional file 2: Figure S2.** TrxIA-2<sub>ic</sub> identification by western blot in eluted fractions from size exclusion chromatography and dithiothreitol reduction analysis. WB was revealed with a rabbit polyclonal serum to IA-2<sub>ic</sub> as primary antibody. A: Identification of monomeric and dimeric forms of TrxIA-2<sub>ic</sub>. Lane 1: affinity purified TrxIA-2<sub>ic</sub> from *E. coli* GI724 strain; lane 2: eluted fraction at V<sub>e</sub> = 8.75 mL, corresponding to dimeric TrxIA-2<sub>ic</sub>; lane 3: eluted fraction at V<sub>e</sub> = 9.79 mL, corresponding to monomeric TrxIA-2<sub>ic</sub>; B: Conversion to TrxIA-2<sub>ic</sub> monomeric form under dithiothreitol reduction. Lane 1: TrxIA-2<sub>ic</sub> under denaturalizing and reducing conditions (8 M urea and 100 mM dithiothreitol). Arrows indicate the electrophoretic mobility of monomeric TrxIA-2<sub>ic</sub>. (PDF 186 kb)

**Additional file 3: Figure S3.** Mass spectrometric analysis of TrxIA-2<sub>ic</sub>. A molecular weight of 55,209.008 Da indicates the major peak consistent with the expected molecular mass of TrxIA-2<sub>ic</sub>. Samples were analyzed on a Bruker Microflex MALDI-TOF device. (PDF 204 kb)

**Additional file 4: Figure S4.** Competitive quantitative assay for TrxIA-2<sub>ic</sub> and TrxIA-2<sub>ic</sub>-biotin synthesized with high rates of biotinylation. Dose-response curves for a pool of 3 IA-2A RBA positive Type 1 diabetic patient sera for different concentrations of TrxIA-2<sub>ic</sub> (open circle, solid line) and TrxIA-2<sub>ic</sub>-biotin (closed circle, dotted line). Parallelism and identity between curves was achieved (one curve adequately fits all data, alpha = 0.05, R<sup>2</sup> = 0.9653). (PDF 111 kb)

**Additional file 5: Figure S5.** IA-2<sub>ic</sub> expression as a fusion protein with Trx in *E. coli* GI724 inclusion bodies. A: SDS-PAGE (12.1 % T 6.0 % C, 1 mm, under reducing conditions, stained with Coomassie Brilliant Blue R-250), B: WB revealed with a rabbit polyclonal serum to thioredoxin as primary antibody. Lanes 1–4: samples from pTrxIA-2<sub>ic</sub> transformed *E. coli* GI724 strain. Lane 1: sample before induction (0 h); lane 2: sample after 1.5 h of induction; lane 3: sample after 3.0 h of induction; lane 4: sample after 16.0 h of induction. Arrows indicate the electrophoretic mobility of TrxIA-2<sub>ic</sub>. (PDF 254 kb)

**Additional file 6: Figure S6.** CL<sub>b</sub>ELISA for IA-2A assessment in 115 healthy control and 60 Type 1 diabetic patient sera. The results are expressed as SDs, the cut-off value (2.5) is indicated by a dotted line and medians for each population are indicated by a dashed line. Out of the 60 patient sera, 34 scored positive (56.7 % sensitivity), whereas 26 patients were negative. Thirty one IA-2A positive sera by RBA scored positive when evaluated by CL<sub>b</sub>ELISA, showing an analytical sensitivity of 59.6 %, SDs ranging from -1.010 to 111.20 and a median SDs = 3.18. Healthy control sera (n = 115) results showed a specificity of 97.4 %. (PDF 237 kb)

## Abbreviations

2ME: 2-mercaptoethanol; <sub>b</sub>cELISA: Blank corrected ELISA with colorimetric detection; CL<sub>b</sub>ELISA: Bridge ELISA with chemiluminescent detection; cps: Counts per second; CV: Column volume; DASP: Diabetes Autoantibody Standardization Program; DM: Diabetes Mellitus; DSG: Dense core secretory granules; EK: Enterokinase; GAD: Glutamic acid decarboxylase; GADA: Glutamic acid decarboxylase autoantibodies; HRP: Horseradish Peroxidase; IA-2: Insulinoma associated protein tyrosine phosphatase 2; IA-2A: Insulinoma associated protein tyrosine phosphatase 2 autoantibodies; IA-2<sub>ic</sub>His<sub>6</sub>: IA-2<sub>ic</sub> fused to a C-terminal His-tag; IAA: Insulin autoantibodies; IASP: Islet Autoantibody Standardization Program; IB: Inclusion bodies; ISF: Intracellular soluble fraction; K<sub>a</sub>: Affinity constant; LADA: Latent autoimmune diabetes of the adults; MS: Mass spectrometry; MW: Molecular weight; ON: Overnight; PBS: Phosphate-buffered saline; PBS-M: 2 % w/v skim milk in PBS; PBS-MT: 2 % w/v skim milk, 0.05 % v/v Tween 20 in PBS; PBS-T: PBS containing 0.05 % v/v Tween 20; PTP: Protein tyrosine phosphatase; RBA: Radioligand binding assay; RIA: Radioimmunoassay; RT: Room temperature; SDs: Standard deviation scores; SDS-PAGE: Sodium dodecyl sulphate-polyacrylamide gel electrophoresis; SEC: Size-exclusion chromatography; T1DM: Type 1 Diabetes mellitus; TBS-MT: 3 % w/v skim milk, 0.05 % v/v Tween 20 in TBS; TBS-T: 0.05 % v/v Tween 20 in TBS; TCL: Total cell lysate; Trx: Thioredoxin; TrxIA-2<sub>ic</sub>: Intracellular domain of IA-2 fused to thioredoxin; V<sub>e</sub>: Elution volume; WB: Western blot; ZnT8: Zinc transporter 8; ZnT8A: Zinc transporter 8 autoantibodies

## Acknowledgments

We thank Liliana Trifone and Adriana Roussos from the Nutrition Service at the Gutiérrez National Pediatric Hospital and the Hemotherapy Division at



the Clinical Hospital José de San Martín (Buenos Aires, Argentina) for collecting and providing the sera of diabetic patients and healthy control individuals, respectively. We also thank Leonardo Alonso for Mass Spectrometry analysis of TrxIA-2<sub>c</sub> MW.

#### Funding

This work was supported in part by grants from FONCYT Program of the National Agency for Science and Technology Promotion (ANPCYT) PICT-2008-0998, National Research Council (CONICET) PIP 11220120100256CO and the University of Buenos Aires, Buenos Aires, Argentina (UBA 20020110100146).

#### Availability of data and materials

The data supporting our findings can be found in the main paper and supplemental material.

#### Authors' contributions

LLG, NIF and SNV conceived and designed the experiments. LLG and NIF performed the experiments. LLG, NIF and SNV analyzed and interpreted the data. AT, EP, RFI and SNV contributed reagents/materials/analysis tools. LLG and SNV wrote the paper. AT, RBD, AVS and RFI contributed with performance of experiments. RFI and SNV supervised the research. All authors read and approved the final manuscript.

#### Competing interests

The authors declare that they have no competing interests.

#### Consent for publication

Not applicable.

#### Ethics approval and consent to participate

Protocols and sample collection from Argentinian healthy individuals without personal or family history of DM or autoimmune diseases and Argentinian Type 1 Diabetic patients were approved by the Ethics Committee of the José de San Martín Clinical Hospital, University of Buenos Aires (UBA), Buenos Aires, Argentina and the Ethics Committees of the Gutiérrez National Pediatric Hospital, Buenos Aires, Argentina, respectively. All subjects were informed about the purpose of the study, and a signed consent for study participation was obtained. Parental consent was obtained for Type 1 Diabetic patients sample collection.

Received: 3 June 2016 Accepted: 21 October 2016

Published online: 24 November 2016

#### References

- Rabin DU, Pleasic SM, Palmer-Crocker R, Shapiro JA. Cloning and expression of IDDM-specific human autoantigens. *Diabetes*. 1992;41:183–6.
- Rabin DU, Pleasic SM, Shapiro JA, Yoo-Warren H, Oles J, Hicks JM, Goldstein DE, Rae PM. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. *J Immunol*. 1994;152:3183–8.
- Lan MS, Lu J, Goto Y, Notkins AL. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. *DNA Cell Biol*. 1994;13:505–14.
- Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. *Proc Natl Acad Sci U S A*. 1996;93:6367–70.
- Solimena M, Dirxk Jr R, Hermel JM, Pleasic-Williams S, Shapiro JA, Caron L, Rabin DU. ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. *EMBO J*. 1996;15:2102–14.
- Barford D, Jia Z, Tonks NK. Protein tyrosine phosphatases take off. *Nat Struct Biol*. 1995;2:1043–53.
- Kim SJ, Jeong DG, Jeong SK, Yoon TS, Ryu SE. Crystal structure of the major diabetes autoantigen insulinoma-associated protein 2 reveals distinctive immune epitopes. *Diabetes*. 2007;56:41–8.
- Trajkovski M, Mziaut H, Schubert S, Kalaidzidis Y, Altkruger A, Solimena M. Regulation of insulin granule turnover in pancreatic beta-cells by cleaved ICA512. *J Biol Chem*. 2008;283:33719–29.
- Mziaut H, Kersting S, Knoch KP, Fan WH, Trajkovski M, Erdmann K, Bergert H, Ehehalt F, Saeger HD, Solimena M. ICA512 signaling enhances pancreatic beta-cell proliferation by regulating cyclins D through STATs. *Proc Natl Acad Sci U S A*. 2008;105:674–9.
- Torii S. Expression and function of IA-2 family proteins, unique neuroendocrine-specific protein-tyrosine phosphatases. *Endocr J*. 2009;56:639–48.
- Schubert S, Knoch KP, Ouwendijk J, Mohammed S, Bodrov Y, Jager M, Altkruger A, Wegbrod C, Adams ME, Kim Y, et al. beta2-Syntrophin is a Cdk5 substrate that restrains the motility of insulin secretory granules. *PLoS One*. 2010;5:e12929.
- Suckale J, Solimena M. The insulin secretory granule as a signaling hub. *Trends Endocrinol Metab*. 2010;21:599–609.
- Ort T, Voronov S, Guo J, Zawalich K, Froehner SC, Zawalich W, Solimena M. Dephosphorylation of beta2-syntrophin and Ca2+/mu-calpain-mediated cleavage of ICA512 upon stimulation of insulin secretion. *EMBO J*. 2001;20:4013–23.
- Tompa P, Buzder-Lantos P, Tantos A, Farkas A, Szilagyai A, Banoczi Z, Hudecz F, Friedrich P. On the sequential determinants of calpain cleavage. *J Biol Chem*. 2004;279:20775–85.
- Mziaut H, Trajkovski M, Kersting S, Ehninger A, Altkruger A, Lemaitre RP, Schmidt D, Saeger HD, Lee MS, Drechsel DN, et al. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. *Nat Cell Biol*. 2006;8:435–45.
- Trajkovski M, Mziaut H, Altkruger A, Ouwendijk J, Knoch KP, Muller S, Solimena M. Nuclear translocation of an ICA512 cytosolic fragment couples granule exocytosis and insulin expression in beta-cells. *J Cell Biol*. 2004;167:1063–74.
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 1997;20:1183–97.
- Castano L, Eisenbarth GS. Type-1 diabetes: a chronic autoimmune disease of human, mouse, and rat. *Annu Rev Immunol*. 1990;8:647–79.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2006, 29 Suppl 1:S43–48.
- Thrower SLBP. What is type 1 diabetes? *Medicine*. 2010;38:592–6.
- Knip M. Can we predict type 1 diabetes in the general population? *Diabetes Care*. 2002;25:623–5.
- Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. *Proc Natl Acad Sci U S A*. 2007;104:17040–5.
- Seissler J, Scherbaum WA. Autoimmune diagnostics in diabetes mellitus. *Clin Chem Lab Med*. 2006;44:133–7.
- Gale EA. Latent autoimmune diabetes in adults: a guide for the perplexed. *Diabetologia*. 2005;48:2195–9.
- Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. *Diabet Med*. 1994;11:299–303.
- Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. *Diabetes*. 1993;42:359–62.
- Payton MA, Hawkes CJ, Christie MR. Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). *J Clin Invest*. 1995;96:1506–11.
- Bonifacio E, Lampasona V, Bingley PJ. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. *J Immunol*. 1998;161:2648–54.
- Xie H, Zhang B, Matsumoto Y, Li Q, Notkins AL, Lan MS. Autoantibodies to IA-2 and IA-2 beta in insulin-dependent diabetes mellitus recognize conformational epitopes: location of the 37- and 40-kDa fragments determined. *J Immunol*. 1997;159:3662–7.
- Dromei JA, Weenink SM, Peters GH, Endl J, Tighe PJ, Todd I, Christie MR. Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. *J Immunol*. 2004;172:4084–90.
- Valdez SN, Poskus E. Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support. *Curr Immunol Rev*. 2010;6:299–313.
- Tiberti C, Verrienti A, Fiore B, Yu L, Eisenbarth GS, Dotta F, Di Mario U. IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes. *Clin Immunol*. 2005;115:260–7.

33. Notkins AL, Zhang B, Matsumoto Y, Lan MS. Comparison of IA-2 with IA-2beta and with six other members of the protein tyrosine phosphatase family: recognition of antigenic determinants by IDDM sera. *J Autoimmun*. 1997;10:245–50.
34. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT, Bottazzo GF, Gale EA. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. *Diabetes*. 1994;43:1304–10.
35. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. *Diabetes*. 1996;45:926–33.
36. Hawa M, Rowe R, Lan MS, Notkins AL, Pozzilli P, Christie MR, Leslie RD. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. *Diabetes*. 1997;46:1270–5.
37. Bonifacio E. Predicting type 1 diabetes using biomarkers. *Diabetes Care*. 2015;38:989–96.
38. Torn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ, Participating L. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. *Diabetologia*. 2008;51:846–52.
39. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. *Lancet*. 1997;350:1288–93.
40. Hagopian WA, Lernmark A, Rewers MJ, Simell OG, She JX, Ziegler AG, Krischer JP, Akolkar B. TEDDY—The Environmental Determinants of Diabetes in the Young: an observational clinical trial. *Ann N Y Acad Sci*. 2006;1079:320–6.
41. Krochik AG, Mazza CS, Valdez SN, Stumpo RR, Papouchado ML, Iacono RF, Cardoso Landaburu AC, Sica MP, Ozuna B, Poskus E. Immunologic and genetic markers in insulin-dependent diabetes mellitus (type 1) in an Argentine population. *Medicina*. 2001;61:279–83.
42. Eisenbarth GS, Jeffrey J. The natural history of type 1A diabetes. *Arq Bras Endocrinol Metabol*. 2008;52:146–55.
43. Gianani R, Rabin DU, Verge CF, Yu L, Babu SR, Pietropaolo M, Eisenbarth GS. ICA512 autoantibody radioassay. *Diabetes*. 1995;44:1340–4.
44. Gonzalez-Buitrago JM, Gonzalez C. Present and future of the autoimmunity laboratory. *Clin Chim Acta*. 2006;365:50–7.
45. Baneyx F. Recombinant protein expression in *Escherichia coli*. *Curr Opin Biotechnol*. 1999;10:411–21.
46. Pines O, Inouye M. Expression and secretion of proteins in *E. coli*. *Mol Biotechnol*. 1999;12:25–34.
47. LaVallie ER, McCoy JM. Gene fusion expression systems in *Escherichia coli*. *Curr Opin Biotechnol*. 1995;6:501–6.
48. Hannig G, Makrides SC. Strategies for optimizing heterologous protein expression in *Escherichia coli*. *Trends Biotechnol*. 1998;16:54–60.
49. LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, McCoy JM. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the *E. coli* cytoplasm. *Biotechnology (N Y)*. 1993;11:187–93.
50. Sica MP, Primo ME, Ermacora MR, Poskus E. High-yield expression of properly folded insulinoma-associated protein intracellular domain (IA-2ic) in *Escherichia coli*. *Biotechnol Appl Biochem*. 2003;37:301–9.
51. Diabetes mellitus. Report of a WHO Study Group. World Health Organization Technical Report Service 1985, 727:1-113
52. Sambrook J, Fritsch EF, Maniatis T. *Molecular cloning: a laboratory manual*. 2nd ed. Cold Spring Harbour: Cold Spring Harbour Laboratory; 1989.
53. Trabucchi A, Guerra LL, Faccinetti NI, Iacono RF, Poskus E, Valdez SN. Surface plasmon resonance reveals a different pattern of proinsulin autoantibodies concentration and affinity in diabetic patients. *PLoS One*. 2012;7:e33574.
54. Hoffman RD, Lane MD. Iodophenylarsine oxide and arsenical affinity chromatography: new probes for dithiol proteins. Application to tubulins and to components of the insulin receptor-glucose transporter signal transduction pathway. *J Biol Chem*. 1992;267:14005–11.
55. Shagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. *Anal Biochem*. 1987;166:368–79.
56. Harlow ELD. *Using Antibodies: a Laboratory Manual*. 1998.
57. Uversky VN. Use of fast protein size-exclusion liquid chromatography to study the unfolding of proteins which denature through the molten globule. *Biochemistry*. 1993;32:13288–98.
58. Valdez SN, Sica MP, Labovsky V, Iacono RF, Cardoso AL, Krochik AG, Mazza CS, Ermacora MR, Cedola N, Poskus E. Combined measurement of diabetes mellitus immunological markers: an assessment of its benefits in adult-onset patients. *Autoimmunity*. 2001;33:227–36.
59. Lobner K, Khoo-Morgenthaler UY, Seissler J, Morgenthaler NG, Scherbaum WA. Detection of autoantibodies to the diabetes-associated antigen IA-2 by a sensitive enzyme-linked immunosorbent assay. *Horm Metab Res*. 1999;31:686–91.
60. Kawasaki E, Yamaguchi H, Hattori H, Egashira T, Eguchi K. Autoantibodies to IA-2 in type 1 diabetes: measurements with a new enzyme-linked immunosorbent assay. *Ann N Y Acad Sci*. 2002;958:241–6.
61. Papouchado ML, Valdez SN, Ermacora MR, Ganan S, Poskus E. Highly-sensitive and specific enzyme-linked immunosorbent assays for GAD65 autoantibodies using a thioredoxin-GAD65 fusion antigen. *J Immunol Methods*. 1997;207:169–78.
62. Chen S, Willis J, Maclean C, Ananieva-Jordanova R, Amoroso MA, Brooking H, Powell M, Collins A, Bennett S, Mitchell S, et al. Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65. *Clin Chim Acta*. 2005;357:74–83.
63. Westerlund-Karlsson A, Suonpaa K, Ankelo M, Ilonen J, Kniip M, Hinkkanen AE. Detection of autoantibodies to protein tyrosine phosphatase-like protein IA-2 with a novel time-resolved fluorimetric assay. *Clin Chem*. 2003;49:916–23.
64. Guerra LL, Trabucchi A, Faccinetti NI, Iacono RF, Ureta DB, Poskus E, Valdez SN. Flow cytometric microsphere-based immunoassay as a novel non-radiometric method for the detection of glutamic acid decarboxylase autoantibodies in type 1 diabetes mellitus. *Analyst*. 2014;139:3017–25.
65. Villalba A, Valdez SN, Iacono RF, Poskus E. Development of 2 alternative enzyme-linked immunosorbent assays for routine screening of glutamic acid decarboxylase autoantibodies. *Clin Chim Acta*. 2007;376:82–7.
66. Goetz H, Kuschel M, Wulff T, Sauber C, Miller C, Fisher S, Woodward C. Comparison of selected analytical techniques for protein sizing, quantitation and molecular weight determination. *J Biochem Biophys Methods*. 2004;60:281–93.
67. Mambetisaeva ET, Martin PE, Evans WH. Expression of three functional domains of connexin 32 as thioredoxin fusion proteins in *Escherichia coli* and generation of antibodies. *Protein Expr Purif*. 1997;11:26–34.
68. Papouchado ML, Valdez SN, Ghiringhelli D, Poskus E, Ermacora MR. Expression of properly folded human glutamate decarboxylase 65 as a fusion protein in *Escherichia coli*. *Eur J Biochem*. 1997;246:350–9.
69. Baer CA, Retief JD, Van Niel E, Braiman MS, Gonzalez-Fernandez F. Soluble expression in *E. coli* of a functional interphotoreceptor retinoid-binding protein module fused to thioredoxin: correlation of vitamin A binding regions with conserved domains of C-terminal processing proteases. *Exp Eye Res*. 1998;66:249–62.
70. Trabucchi A, Guerra LL, Faccinetti NI, Iacono RF, Poskus E, Valdez SN. Expression and characterization of human proinsulin fused to thioredoxin in *Escherichia coli*. *Appl Microbiol Biotechnol*. 2012;94:1565–76.
71. McCoy J, Lavallie E. Expression and purification of thioredoxin fusion proteins. *Curr Protoc Mol Biol* 2001, Chapter 16:Unit 16 18.
72. Jia X, Li G, Chen Z, Xu G, Xie C, Zhang D, Zhou W, Zheng S, Xie X, Yang J, et al. Expression and identification of type 1 diabetes associated autoantigen IA-2. *Chin Med J (Engl)*. 2003;116:524–8.
73. Morgenthaler NG, Lobner K, Morgenthaler UY, Christie MR, Seissler J, Scherbaum WA. Recombinant IA-2 expressed in *E. coli* can be used for the routine detection of autoantibodies in Type-1 diabetes. *Horm Metab Res*. 1998;30:559–64.
74. Burbelo PD, Hirai H, Leahy H, Lernmark A, Ivarsson SA, Iadarola MJ, Notkins AL. A new luminescence assay for autoantibodies to mammalian cell-prepared insulinoma-associated protein 2. *Diabetes Care*. 2008;31:1824–6.
75. Masuda M, Powell M, Chen S, Beer C, Fichna P, Rees Smith B, Furmaniak J. Autoantibodies to IA-2 in insulin-dependent diabetes mellitus. Measurements with a new immunoprecipitation assay. *Clin Chim Acta*. 2000;291:53–66.
76. Palomer X, Mauricio D, Rodríguez-Espinosa J, Zapico E, Mayoral C, González-Sastre F, de Leiva A, Blanco-Vaca F. Evaluation of Two Nonisotopic Immunoassays for Determination of Glutamic Acid Decarboxylase and Tyrosine Phosphatase Autoantibodies in Serum. *Clin Chem*. 2004;50:1378–82.

77. Kikkas I, Mallone R, Larger E, Volland H, Morel N. A rapid lateral flow immunoassay for the detection of tyrosine phosphatase-like protein IA-2 autoantibodies in human serum. *PLoS One*. 2014;9:e103088.
78. Elvers KT, Geoghegan I, Shoemark DK, Lampasona V, Bingley PJ, Williams AJ. The core cysteines, (C909) of islet antigen-2 and (C945) of islet antigen-2beta, are crucial to autoantibody binding in type 1 diabetes. *Diabetes*. 2013;62:214–22.
79. Krause S, Chmiel R, Bonifacio E, Scholz M, Powell M, Furmaniak J, Rees Smith B, Ziegler AG, Achenbach P. IA-2 autoantibody affinity in children at risk for type 1 diabetes. *Clin Immunol*. 2012;145:224–9.
80. Trabucchi A, Iacono RF, Guerra LL, Faccinetti NI, Krochik AG, Arriazu MC, Poskus E, Valdez SN. Characterization of insulin antibodies by Surface Plasmon Resonance in two clinical cases: brittle diabetes and insulin autoimmune syndrome. *PLoS One*. 2013;8:e84099.
81. Berzofsky JA, Schechter AN. The concepts of crossreactivity and specificity in immunology. *Mol Immunol*. 1981;18:751–63.
82. Villalba A, Iacono RF, Valdez SN, Poskus E. Detection and immunochemical characterization of glutamic acid decarboxylase autoantibodies in patients with autoimmune diabetes mellitus. *Autoimmunity*. 2008;41:143–53.
83. Stumpo RR, Llera AS, Cardoso AI, Poskus E. Solid versus liquid phase assays in detection of insulin antibodies. Influence of iodination site on labelled insulin binding. *J Immunol Methods*. 1994;169:241–9.
84. Sodoyez-Goffaux F, Koch M, Dozio N, Brandenburg D, Sodoyez JC. Advantages and pitfalls of radioimmune and enzyme linked immunosorbent assays of insulin antibodies. *Diabetologia*. 1988;31:694–702.
85. Sodoyez JC, Koch M, Lemaire I, Sodoyez-Goffaux F, Rapaille A, Francois-Gerard C, Sondag D. Influence of affinity of antibodies upon their detection by liquid phase radiobinding assay and solid phase enzyme linked immunosorbent assay. Demonstration using monoclonal antibodies raised against rDNA human proinsulin. *Diabetologia*. 1991;34:463–8.
86. Richardson CC, McLaughlin KA, Brown TJ, Morgan D, Feltbower R, Powell M, Furmaniak J, Rees Smith B, Christie MR. Failure to detect anti-idiotypic antibodies in the autoimmune response to IA-2 in Type 1 diabetes. *Autoimmunity*. 2013;46:375–81.
87. Spangler BD. Binding to native proteins by antipeptide monoclonal antibodies. *J Immunol*. 1991;146:1591–5.
88. Palmer JP, Wilkin TJ, Kurtz AB, Bonifacio E. The Third International Workshop on the Standardisation of Insulin Autoantibody Measurement. *Diabetologia*. 1990;33:60–1.
89. Levy-Marchal C, Bridel MP, Sodoyez-Goffaux F, Koch M, Tichet J, Czernichow P, Sodoyez JC. Superiority of radiobinding assay over ELISA for detection of IAAs in newly diagnosed type 1 diabetic children. *Diabetes Care*. 1991;14:61–3.
90. Berzofsky JA, Berkower IJ, Epstein SL. Antigen-Antibody Interactions and Monoclonal Antibodies. In: Paul WE, editor. *Fundamental Immunology*. 3rd ed. New York: Raven Press; 1993. p. 421–65.
91. Zhao Z, Miao D, Michels A, Steck A, Dong F, Rewers M, Yu L. A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease. *J Immunol Methods*. 2016;430:28–32.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

